---
agent: records-analyst
company: meridian-health
task: records-request
generated: "2026-02-21T14:02:00Z"
model: anthropic/claude-opus-4-6
---

# Medical Records Request Processing Summary

**Meridian Health Partners — Records Management Division**

---

## Request Acknowledgment

| Field | Detail |
|---|---|
| **Request ID** | RR-018 |
| **Date Received** | February 12, 2026 |
| **Patient** | Catherine Dubois |
| **Requesting Facility** | Oregon Dermatology Institute |
| **Record Type** | Biologic Therapy Records |
| **Urgency** | Standard |
| **Processing Agent** | Records Analyst (AI-Assisted) |

This request has been received and logged into the Meridian Health Partners records management system. The requesting facility has been notified of receipt via secure fax confirmation.

---

## Records Identified and Status

The following records have been located in the patient's electronic health record (EHR):

| Record | Date Range | Status |
|---|---|---|
| Biologic therapy initiation notes | 2024-06-15 | ✅ Located |
| Infusion session logs (adalimumab) | 2024-06 – 2025-09 | ✅ Located |
| Transition to ustekinumab — clinical rationale | 2025-09-22 | ✅ Located |
| Ustekinumab infusion records | 2025-10 – 2026-02 | ✅ Located |
| Associated lab work (CBC, CMP, TB screening) | 2024-06 – 2026-01 | ✅ Located |
| Adverse event documentation | 2025-03-11 (injection site reaction) | ✅ Located |
| Provider correspondence re: therapy switch | 2025-08 – 2025-09 | ✅ Located |

**Total Pages:** 47 pages across 7 document sets.

All records are complete and ready for compilation.

---

## Estimated Completion Time

| Milestone | Target |
|---|---|
| Records compilation | February 22, 2026 |
| Quality review & redaction check | February 23, 2026 |
| Release authorization | February 24, 2026 |
| **Delivery to requesting facility** | **February 25, 2026** |

Standard processing (10 business days from receipt). Current status: **on track** — Day 7 of 10.

---

## Secure Transfer Method

- **Primary:** HL7 FHIR-compliant secure electronic transfer via Meridian Health Partners HIE gateway
- **Fallback:** Encrypted PDF via Direct Secure Messaging (DSM) to Oregon Dermatology Institute's registered endpoint
- **Verification:** Requesting provider must confirm receipt within 48 hours; unconfirmed transfers trigger follow-up

Oregon Dermatology Institute's DSM endpoint has been verified as active in the DirectTrust network.

---

## Compliance Checklist

| Requirement | Status |
|---|---|
| Valid authorization on file (signed by patient) | ✅ Verified — signed 2026-02-10 |
| Requesting provider identity confirmed | ✅ NPI 1841293756 verified |
| Minimum necessary standard applied | ✅ Only biologic therapy records included |
| Psychotherapy notes excluded (42 CFR Part 2) | ✅ N/A — none in scope |
| Substance abuse records excluded (if applicable) | ✅ N/A — none in scope |
| HIV/STI records — special consent check | ✅ N/A — none in scope |
| Audit trail entry created | ✅ Logged 2026-02-12 14:33 PST |
| Patient notification of disclosure | ✅ Mailed 2026-02-13 |
| Retention of request documentation (6 years) | ✅ Archived |

**Compliance Status: CLEAR** — No holds, no restrictions, no pending litigation flags.

---

## Notes

- Patient has an active care relationship with both Meridian Health Partners (primary care) and the requesting facility (specialty dermatology). Transfer is clinically appropriate.
- Biologic therapy records contain weight-based dosing calculations — requesting provider should verify current weight at next visit.
- Next scheduled infusion at Meridian: March 8, 2026. Coordination with receiving facility recommended if transfer of care is intended.

---

*This summary was generated by the Meridian Health Partners Records Analyst agent. All records transfers are subject to final review by the Health Information Management (HIM) department.*
